Hikma calls off Injectables sale
This article was originally published in Scrip
Hikma has decided against selling off its global Injectables business, which analysts had valued at up to $2.2 billion (scripintelligence.com, 4 March 2013). The Jordanian headquartered company Hikma had been conducting a strategic review of options following significant interest in the unit apparently sparked Mylan's $1.6 billion acquisition of Strides Arcolab's similar business Agila Specialities earlier this year. Companies such as Pfizer and Novartis were rumored to have been disappointed bidders for Agila (scripintelligence.com, 28 February 2012).